Robertson Stephens Wealth Management LLC Reduces Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Robertson Stephens Wealth Management LLC decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 41.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,377 shares of the medical research company’s stock after selling 4,435 shares during the quarter. Robertson Stephens Wealth Management LLC’s holdings in Edwards Lifesciences were worth $472,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its holdings in Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after buying an additional 14,610,123 shares during the period. State Street Corp grew its holdings in Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock valued at $1,733,270,000 after buying an additional 256,538 shares during the period. Geode Capital Management LLC grew its holdings in Edwards Lifesciences by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock valued at $889,050,000 after buying an additional 284,918 shares during the period. Fisher Asset Management LLC lifted its stake in shares of Edwards Lifesciences by 9.8% in the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after purchasing an additional 806,705 shares in the last quarter. Finally, Jennison Associates LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $555,939,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $70.38 on Friday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $41.51 billion, a price-to-earnings ratio of 10.16, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. The business has a 50 day simple moving average of $72.47 and a 200-day simple moving average of $69.55.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,000 shares of company stock worth $547,430. 1.27% of the stock is currently owned by insiders.

Analyst Ratings Changes

EW has been the topic of several research analyst reports. The Goldman Sachs Group lifted their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Royal Bank of Canada lifted their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average target price of $79.19.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.